| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-07-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-07-2024 | 12-31-2023 | 10-K | |
| 3 | 11-01-2023 | 09-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate.
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow tra...
Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study...
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
